AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 11 - (NewsRx.com & NewsRx.net) -- DNA fusion vaccine components were able to induce protective cytotoxic T cells against a single epitope of a tumor antigen, according to a recent study.
"DNA vaccines can activate immunity against tumor Ags [antigens] expressed as MHC class I-associated peptides. However, priming of CD8+ CTL [cytotoxic T lymphocytes] against weak tumor Ags may require adjuvant molecules," said J. Rice and colleagues, Southampton University Hospital Trust.
These researchers "used a pathogen-derived sequence from tetanus toxin (fragment C (FrC)) fused to tumor Ag sequences to promote Ab and CD4+ T-cell responses. For induction of CD8+ T-cell responses, the FrC sequence has been engineered to remove potentially competitive MHC class I-binding epitopes and to improve presentation of tumor epitopes."
According to their study report, "The colon carcinoma CT26 expresses an endogenous retroviral gene product, gp70, containing a known H2-L-d-restricted epitope (AH1). A DNA vaccine encoding gp70 alone was a poor inducer of CTL, and performance was not significantly improved by fusion of full-length FrC. However, use of a minimized domain of FrC, with the AM sequence fused to the 3' position, led to rapid induction of high levels of CTL."
"IFN [interferon]-gamma-producing epitope-specific CTL were detectable ex vivo and these killed CT26 targets in vitro," reported Rice and colleagues.
"The single epitope ...
Source: HighBeam Research, DNA fusion vaccine components induce protective CTL against a single...